🫀 At a press conference in Osaka on October 21, 2026, a woman in her 50s told reporters that about a week after her operation, she found she could breathe deeply again. The first thing she wants to do, she said, is take her dog for a walk.

On September 29, 2026, surgeons had placed three thin sheets of heart muscle cells, grown from donor iPS cells, on the surface of her heart. It was the first time an approved iPS cell product had been used on a patient in routine care covered by public health insurance. The product, RiHEART, carries an insurance price of 53.2 million yen. And she is also the first of 75 patients whose results will decide whether it can stay on the market at all.

What Was Actually a First

iPS cell heart sheets are not new to patients. A team led by Osaka University heart surgeon Yoshiki Sawa transplanted the first one in a clinical trial in January 2020, and eight patients were evaluated in that trial. On March 6, 2026, Japan's health ministry approved RiHEART, developed by Cuorips, an Osaka University spinoff, along with Sumitomo Pharma's Parkinson's disease treatment Amchepry. They were the world's first approved products made from iPS cells (how that approval came about). Japan's drug and device regulator, the PMDA, noted that as of November 2025, RiHEART was not approved anywhere else.

Approval is not the same as treatment. Amchepry was added to the insurance price list first, in May (the May pricing decision), but Sumitomo Pharma said in July that its first post-launch transplant was planned for October (the Kyoto plan). RiHEART was covered from September 1, 2026. Four weeks later, at Osaka Keisatsu Hospital (Osaka Police Hospital), Sawa operated. The surgery took about 50 minutes.

Sawa, now president of the hospital and a professor emeritus at Osaka University, is also a director and chief medical science officer at Cuorips. The surgeon who operated, and who runs the hospital reporting on the case, is an executive of the company that sells the product.

According to the hospital, the patient started walking rehab two days after surgery and her recovery was going well. As of the October 21 press conference, she was scheduled to go home on October 22, 2026. The hospital expects any improvement to come gradually over several months. One patient, three weeks after chest surgery, cannot show how much of her recovery is the sheet and how much is the operation healing.

A 53.2-Million-Yen Price Tag

On July 22, 2026, Japan's Central Social Insurance Medical Council (Chuikyo), the panel that sets prices for the public insurance system, approved a reimbursement price of 53.2 million yen (about $338,000 at 157.58 yen to the dollar on October 22, 2026). It can be billed once per patient, for a set of three sheets; the surgery is billed separately.

Patients pay far less: Japan's high-cost medical expense system caps monthly out-of-pocket costs according to income.

The ministry counts 690 eligible patients in the first year, but projects that even at its peak, in year 10, the sheet will be used on 96 patients a year, for annual sales of 5.11 billion yen (about $32.4 million). The approval requires surgeons experienced in open-chest surgery and severe heart failure, working at hospitals equipped for it. A ministry official told the council it expects about 20 facilities nationwide during the conditional period. The Osaka hospital says it is considering the operation for 10 more patients.

Two Out of Eight

The approval rests on a single trial of eight patients, with no control group, in which everyone knew who had been treated. Before it began, the investigators chose one main yardstick: whether the left ventricular ejection fraction (LVEF), the share of blood the heart's main pumping chamber pushes out with each beat, rose by 5 points or more 26 weeks after transplant.

Two of the eight met it. In the PMDA's patient-by-patient tables, three of the eight saw that number fall by 5 points or more at 26 weeks.

Other measures looked better. At 52 weeks, 4 of 7 patients tested had raised their peak oxygen uptake during exercise by 10% or more, a change doctors consider meaningful. All 8 moved up at least one class on the NYHA scale, which grades how much heart failure limits daily life. The trial doctors judged all 8 cases effective at 52 weeks.

The PMDA accepted the product, but carefully. It wrote that judging effectiveness from improved symptoms has limits when some objective measures got worse, and that because the trial was open-label, psychological effects could not be ruled out. It concluded that no patient had clearly worsened because of the transplant. There were no deaths and no side effects attributed to the product itself, though five patients had adverse events that could not be ruled out as linked to the surgery, and seven had events possibly linked to the immunosuppressants that patients take for 90 days.

How the sheet works is not settled either. Each sheet carries about 33 million heart muscle cells, about 100 million for three. Cuorips says the cells release signaling proteins that encourage new blood vessels and reduce scarring, a so-called paracrine effect, and expects them to stay about three months and vanish within six. The PMDA said it is unclear whether that effect is the whole story, noted that nobody knows how long the cells survive in humans, and made studying the mechanism a condition of approval.

Some in Japan oppose the approval outright. On April 6, 2026, the drug-safety group Medwatcher Japan asked the health minister to revoke the approval and asked Chuikyo not to cover it, pointing to the two-in-eight result.

The First of 75

That is why the approval has an expiry date. It runs for seven years, to March 2033. In that time Cuorips must follow every treated patient and come back with proof. The post-marketing study targets 75 patients and compares them with 150 similar patients who did not receive the sheet, drawn from outside data. Cuorips estimates about 88 patients will be enrolled within five years.

The yardstick has changed, too. Instead of LVEF, the study will measure the share of patients whose peak oxygen uptake rises 10% or more at 52 weeks while the left ventricle does not enlarge. At the July Chuikyo meeting, a member from the National Federation of Health Insurance Societies said he took this not as a way to make the benefit easier to show, but as adding more clinically meaningful measures. A ministry official added that patients must be told in writing that the clinical data are limited, and must give written consent.

The Terumo Precedent

In September 2015, Terumo won conditional, time-limited approval for HeartSheet, a sheet made from the patient's own skeletal muscle cells, for heart failure. Terumo tracked every treated patient as required and reapplied in September 2023. In July 2024, the government's expert panel concluded the data did not show effectiveness and judged approval inappropriate. Terumo stopped selling the product. Safety was not the problem.

RiHEART uses different cells and a different study design, but the rule is the same: if the post-market data fall short, full approval does not follow. SanBio's brain-injury cell therapy Akuugo, approved under the same system, faces the same clock (Akuugo's first commercial patient).

China Takes a Different Route

No iPS-derived product appears to be approved in the US or Europe. China, though, is moving fast on a different path. In August 2026, Nature Medicine published HEAL-CHF, a randomized trial of 20 patients with advanced ischemic heart failure, by a team at Nanjing Drum Tower Hospital. Surgeons injected donor iPS-derived heart cells directly into the heart muscle during bypass surgery, and compared the results with bypass alone.

At 12 months, the cell group did better on six-minute walking distance and blood flow to the heart muscle, but showed no difference in ejection fraction or NYHA class. All 10 patients in the cell group developed an abnormal heart rhythm in the first weeks, and two had ventricular tachycardia that needed electrical cardioversion. The authors say the balance of risk and benefit is still to be worked out.

Treatment First, Proof Later

Japan chose to put RiHEART into insured care first and gather the proof afterward, so that people with severe heart failure and few options do not have to wait.

If a treatment like this were offered in your country, should public insurance pay for it before the benefit is proven, or should patients wait for the evidence?

References